Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from Analysts
Why Vir Biotechnology (VIR) Is Up 5.1% After Astellas Cancer Deal And Equity Raise News
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $20.00 - Zolmax
Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - Daily Political
Weekly Analysts' Ratings Changes for Vir Biotechnology (VIR) - Daily Political
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - Markets Daily
Vir Biotechnology Inc. (VIR) - Insider Monkey
Reviewing Werewolf Therapeutics (NASDAQ:HOWL) and Vir Biotechnology (NASDAQ:VIR) - Daily Political
Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,400.48 in Stock - Markets Daily
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen
Why Vir Biotechnology (VIR) Is Up 20.2% After Astellas Deal And $150 Million Equity Raise
Vir Biotechnology (NASDAQ:VIR) EVP Sells $33,115.25 in Stock - Markets Daily
Vir Biotechnology (NASDAQ:VIR) EVP Mark Eisner Sells 1,616 Shares - Daily Political
Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 1,889 Shares of Stock
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 13,700 Shares
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 42,377 Shares
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 42,377 Shares of Stock - Markets Daily
Company Website: https://vir.bio SAN FRANCISCO -- (Busines
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - Stock Observer
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares - Stock Observer
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Should You Sell?
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Three Biotechs With the Right Formula - TheStreet Pro
Vir Biotechnology (NASDAQ:VIR) Sees Strong Trading Volume Following Analyst Upgrade - Markets Daily
Vir Biotechnology (NASDAQ:VIR) Sees Large Volume Increase After Analyst Upgrade - Stock Observer
Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results, Beats Expectations By $0.11 EPS - Stock Observer
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CEO Sells 19,039 Shares of Stock
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CAO Sells 1,829 Shares of Stock
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 2,089 Shares of Stock
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,089 Shares of Stock
Verneuil Vanina De Sells 4,445 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Assessing Vir Biotechnology (VIR) Valuation After A Strong Year To Date Share Price Rebound
Vir Biotechnology (NASDAQ:VIR) CEO Sells $141,840.55 in Stock - Stock Observer
5 Stocks I'm Buying While the Crowd Focuses on AI Disaster - TheStreet Pro
Anthropic expands Claude AI chatbot, Keurig Dr Pepper's Q4 beat
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High After Earnings Beat
Promising Small Cap Stocks To Follow Now - February 24th - Stock Observer
Vir Biotech Soars On Global Collaboration With Astellas, Encouraging Prostate Cancer Drug Data
Vir Biotechnology Shares Jump Over 50% After Positive Phase 1 VIR-5500 Prostate Cancer Data
Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...
Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS
Vir Biotechnology Q4 Earnings Call Highlights - Stock Observer
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Morningstar
Astellas and Vir Biotechnology Announce Global Strategic Col
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Morningstar
Japan's Astellas announces $1.37 B deal with Vir Biotechnology to develop T-Cell therapies for prostate cancer
Vir Biotechnology (NASDAQ:VIR) CAO Sells $11,918.70 in Stock
Aberdeen Group plc Purchases 519,374 Shares of Vir Biotechnology, Inc. $VIR
Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts
Vir Biotechnology (VIR) Projected to Post Earnings on Monday
VirBiotechnology News
Fed Policy at Crossroads: Geopolitical Shocks and Inflationary Pressures
Wall Street Strategists Maintain Bullish Stance on US Equities Amidst Geopolitical Risks
Bank of America Raises 2026 Brent Crude Forecast Amidst Hormuz Strait Disruptions
Crypto price prediction: XRP up or down, ETH price target, will BTC surge again?
Commodity trading in Dubai, UAE: real time gold prices, XAU/USD prediction for 2026
Top growth stocks to buy in 2026: Rivian (RIVN) stock, SanDisk (SNDK) stock, Robinhood (HOOD)
Latest news
Show moreUkraine Peace Talks Nearing Stalemate Amid Shifting US Focus to Iran Conflict
Fed Nominee Warsh Confirmation Delayed Amidst Financial Scrutiny and Political Hurdles
Tungsten Market Crunch: Rising Military Demand Pushes Prices to Record Highs
Iran Calls for "Thorough Re-evaluation" of Gulf Relations Amidst US-Israeli War
